Catalyst overview
Research summary
This catalyst tracks a Phase 1a data readout for CX-801 +/- KEYTRUDA in Cancer, Solid tumor/s, Melanoma. The expected timing is based on the latest available company guidance and may change.
In collab w/ MRK. 1/24/24- IND cleared. 1/6/25- Dose escalation ongoing. 11/06/25:- Ph1 mono biomarkers positive, combo data in 2026. 11/8/25– Monotx biomarker data at SITC'25. 01/08/26:- CX-801 Ph1 monotherapy escalation reached fourth dose, well tolerated. Keytruda combo escalation ongoing; initial data expected end 2026. 03/16/26:- CX-801 Keytruda combo enrolling 2nd dose; first combo data expected end 2026.05/07/26:- CX-801 monotherapy tolerated beyond approved IFNα2b; combo now at third dose level, initial Keytruda data expected end 2026. 08/06/26:- Combo cleared third dose. Initial Keytruda combo data now expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.